Skip to content

The effect of liposomal bupivacaine versus ropivacaine in serratus anterior plane block on postoperative pain in patients undergoing video-assisted thoracoscopic surgery: a prospective, randomized controlled Study

The effect of liposomal bupivacaine versus ropivacaine in serratus anterior plane block on postoperative pain in patients undergoing video-assisted thoracoscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119652
Enrollment
Unknown
Registered
2026-03-02
Start date
2026-03-05
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after video-assisted thoracoscopic surgery in patients with pulmonary tumors

Interventions

Group RP:For patients undergoing ultrasound-guided superficial serratus anterior plane block, subjects in the RP group received 0.5% ropivacaine (150 mg, 30 ml)
Group LB :For patients undergoing ultrasound-guided superficial serratus anterior plane block, subjects in the LB group received liposomal bupivacaine (266 mg, diluted to 30 ml)

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective thoracoscopic lung tumor resection under general anesthesia for the first time; 2. Aged 18–65 years, with body mass index (BMI) ranging from 18.5 to 30 kg/m^2, regardless of gender; 3. Classified as American Society of Anesthesiologists (ASA) Physical Status Class ?–?.

Exclusion criteria

Exclusion criteria: 1. Patients who are pregnant. 2. Patients with a history of allergies to anesthetics associated with general anesthesia or nerve block. 3. Patients with a history of chronic pain and long-term oral administration of non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics. 4. Patients with infection, rash at the chest wall puncture site, or severe coagulation disorders. 5. Patients with severe psychological or psychiatric diseases, or communication disorders. 6. Patients with severe liver dysfunction, whose preoperative alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceed twice the normal value. 7. Patients who have participated in other clinical trials within the past four weeks

Design outcomes

Primary

MeasureTime frame
The incidence of chronic postsurgical pain at 3-month follow-up;

Secondary

MeasureTime frame
Satisfaction level of participants;Short-term postoperative analgesic efficacy;Intraoperative remifentanil dosage;sufentanil consumption in the patient-controlled analgesia (PCA) pump within 72 hours postoperatively;Total number of patient-controlled analgesia (PCA) pump presses by the subjects within 72 hours postoperatively;Safety indicators;Morphine rescue consumption within 72 hours postoperatively;Time to thoracic drainage tube removal in the subjects;Time to first ambulation after surgery in the subjects;Total hospitalization costs during the subjects' stay;Postoperative length of hospital stay in the subjects;

Countries

China

Contacts

Public ContactAn Lixin

Beijing Friendship Hospital, Capital Medical University

anlixin8120@163.com+86 138 1024 8120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026